Versor Investments LP Raises Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Versor Investments LP raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 93.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,565 shares of the medical equipment provider's stock after buying an additional 8,965 shares during the period. Versor Investments LP's holdings in Zimmer Biomet were worth $2,004,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in shares of Zimmer Biomet by 12.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock valued at $1,404,638,000 after buying an additional 1,215,935 shares during the period. American Century Companies Inc. raised its holdings in shares of Zimmer Biomet by 12.6% in the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock worth $391,239,000 after purchasing an additional 411,163 shares during the period. Victory Capital Management Inc. boosted its stake in shares of Zimmer Biomet by 6.7% during the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock valued at $365,163,000 after purchasing an additional 211,637 shares in the last quarter. Finally, Boston Partners raised its stake in Zimmer Biomet by 26.3% in the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock worth $437,413,000 after buying an additional 691,191 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

NYSE:ZBH traded up $1.35 during mid-day trading on Monday, hitting $109.53. The company's stock had a trading volume of 1,404,545 shares, compared to its average volume of 1,490,628. The business's fifty day moving average is $106.37 and its two-hundred day moving average is $110.33. The stock has a market cap of $21.80 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 1.99 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the business earned $1.65 earnings per share. The company's revenue was up 4.1% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 18.25%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent research reports. Robert W. Baird dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research report on Thursday, August 8th. Wolfe Research started coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a "peer perform" rating for the company. UBS Group cut their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating on the stock in a research report on Thursday, August 8th. Canaccord Genuity Group lowered their target price on shares of Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, September 10th. Finally, TD Cowen reduced their price target on Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating on the stock in a research report on Friday, September 6th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and an average target price of $124.11.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.